Astria Therapeutics, Inc.
ATXS
$7.49
-$0.04-0.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.12% | 23.69% | 34.48% | 37.75% | 44.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.55% | 58.50% | 64.46% | 59.96% | 66.79% |
| Operating Income | -42.55% | -58.50% | -64.46% | -59.96% | -66.79% |
| Income Before Tax | -25.40% | -32.35% | -29.32% | -82.75% | -90.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.40% | -32.35% | -29.32% | -82.75% | -90.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.40% | -32.35% | -29.32% | -82.75% | -90.23% |
| EBIT | -42.55% | -58.50% | -64.46% | -59.96% | -66.79% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 12.39% | 19.27% | 28.48% | 4.86% | 5.73% |
| Normalized Basic EPS | -6.97% | 1.62% | 12.99% | 23.78% | 22.78% |
| EPS Diluted | 12.39% | 19.27% | 28.48% | 4.86% | 5.73% |
| Normalized Diluted EPS | -6.97% | 1.62% | 12.99% | 23.78% | 22.78% |
| Average Basic Shares Outstanding | 33.78% | 59.02% | 86.42% | 98.28% | 96.66% |
| Average Diluted Shares Outstanding | 33.78% | 59.02% | 86.42% | 98.28% | 96.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |